● 本报记者罗京 标准是中医药走向世界的关键通行证。"一套标准体系的成型，不仅为核心产品进入海外市场提供了通 行凭证，也让寿仙谷（603896）在中医药国际化进程中找到了差异化的突破口。"寿仙谷副董事长、植 物药研究院院长李振皓近日在接受中国证券报记者专访时表示，截至目前，寿仙谷已主导、参与制定中 医药各类标准100余项，其中国际标准8项、已发布5项，公司正以标准话语权为抓手，持续推动中医药 国际化。 打造中医药全球通行的质量语言 目前，寿仙谷建立了"优良品种选育→适生调控栽培→智能制造→产品研发→药理临床研究"一整套的中 药全产业链标准化体系，确保产品"安全有效、稳定可控"。 在育种环节，寿仙谷通过自主选育成功获得12个中药材新品种，包括灵芝、铁皮石斛、西红花、杭白菊 等道地药材。在加工环节，公司研发的去壁纯化技术已斩获中国、美国、欧盟、日本、韩国等多国发明 专利授权。 李振皓表示，寿仙谷的研发路径也随着企业发展不断优化完善。"前期我们在功能基因挖掘、作用机制 解析等基础研究领域投入较多，建立了高端科研平台，为后续产品开发等研究奠定了良好基础。近年 来，我们加快把这些技术转化为高品质产品，核心目标就是让科技 ...

中医药国际化之路，长期受困于中外标准体系差异形成的市场准入壁垒。寿仙谷也曾尝试推动中药以药 品身份在海外注册，但李振皓表示，经过系统研究后发现，这一路径面临审批周期长、临床成本高、诊 疗体系差异大等多重现实挑战。 ● 本报记者 罗京 标准是中医药走向世界的关键通行证。"一套标准体系的成型，不仅为核心产品进入海外市场提供了通 行凭证，也让寿仙谷在中医药国际化进程中找到了差异化的突破口。"寿仙谷副董事长、植物药研究院 院长李振皓近日在接受中国证券报记者专访时表示，截至目前，寿仙谷已主导、参与制定中医药各类标 准100余项，其中国际标准8项、已发布5项，公司正以标准话语权为抓手，持续推动中医药国际化。 打造中医药全球通行的质量语言 "于是我们转向国际标准化建设，希望换一种方式，为中医药建立起全球通行的质量语言。"李振皓说。 2011年，寿仙谷正式启动灵芝、铁皮石斛等中药的ISO国际标准的立项工作。彼时，企业对国际标准化 组织/传统医药技术委员会（ISO/TC249）的申报流程尚处陌生阶段，相关提案连续三年未能通过国内遴 选，直至2015年，两项标准才在ISO/TC249第六次全体会议上通过答辩，初步立项。随后，项目 ...

Core Viewpoint - The company, Shouxiangu (603896), has provided insights into its R&D expenses as a percentage of revenue for the years 2021 to 2024, indicating a stable trend without a year-on-year decline [1] Group 1: R&D Expenses Overview - For the years 2021 to 2024, the R&D expenses as a percentage of revenue are projected to be 6.33%, 5.77%, 6.33%, and 7.00% respectively [1] - In the period from January to September 2024, the R&D expenses as a percentage of revenue are reported to be 9.79%, which is considered a normal fluctuation [1] - The company emphasizes that there has not been a trend of decreasing R&D expenses year-on-year, as confirmed by its previous periodic reports [1]

Group 1 - The company disclosed a related party transaction plan for 2026, involving the procurement of goods worth 20 million yuan and sales of goods worth 6.2 million yuan, which requires shareholder approval and may impact operations [2] - The company is not currently investing in short videos or short dramas but is promoting its brand through platforms like Douyin and WeChat, while its parent company is involved in the film "Unbreakable" [3] - The company has experienced continuous net outflows of main funds since early January 2026, potentially due to market style rotation and short-term pressure on the traditional Chinese medicine sector [4] Group 2 - The company is expanding its market presence outside Zhejiang Province, focusing on fast-moving consumer goods development and digital empowerment as part of its long-term strategy [5] - The traditional Chinese medicine industry is driven by aging demographics and policy support, but there are risks associated with deepening centralized procurement policies and fluctuations in raw material costs [6]

Core Viewpoint - Shouxiangu (603896) has not yet engaged in external investments related to short videos and short dramas, focusing instead on brand promotion and product sales through new media platforms like Douyin, WeChat Video, and Xiaohongshu [1] Group 1 - The company is currently leveraging new media platforms for brand promotion and product sales [1] - Future strategies will involve a careful assessment of the collaborative value of various new media formats in brand building and market education [1] - The company aims to promote the innovative dissemination of traditional Chinese medicine culture [1] Group 2 - A new romantic film titled "Unbreakable" produced by the company's parent, Zhejiang Shouxiangu Investment Management Co., has been released on iQIYI [1] - The film is produced by Zhang Jizhong, who serves as both the producer and director [1] - Investors are encouraged to watch the film [1]

Core Viewpoint - Shouxiangu (603896.SH) has not yet engaged in external investments related to short videos and short dramas, focusing instead on brand promotion and product sales through new media platforms like Douyin, WeChat Video Accounts, and Xiaohongshu [1] Group 1 - The company is currently leveraging new media platforms for brand promotion and product sales [1] - Future strategies will involve a careful assessment of the collaborative value of various new media formats in brand building and market education [1] - The company aims to promote the innovative dissemination of traditional Chinese medicine culture [1]

Core Viewpoint - Shouxiangu has developed a proprietary wall-breaking technology for Ganoderma lucidum spore powder, which has received multiple international patents and is recognized as an internationally leading technology [2] Group 1: Technology and Intellectual Property - The wall-breaking technology for Ganoderma lucidum spore powder is a unique core technology of the company [2] - The technology has been granted national invention patents as well as patents in Japan, the United States, Europe, South Korea, and South Africa, establishing a comprehensive independent intellectual property protection system [2] Group 2: Health Benefits and Efficacy - Research results indicate that the triterpenes in the wall-broken Ganoderma lucidum spore powder can directly inhibit the growth and metastasis of tumor cells [2] - Ganoderma polysaccharides can regulate the immune system, enhance the body's defense capabilities, alleviate excessive inflammatory responses, and balance immune checkpoints [2] - The product helps reduce common adverse reactions caused by tumor surgeries, chemotherapy, and targeted therapies, such as fatigue, bone marrow suppression, emotional distress, and sleep disorders, thereby improving patients' quality of life and creating a synergistic effect with conventional anti-tumor treatments [2]

Group 1 - The company Shouxiangu (603896) is currently working on the expansion of its pre-processing workshop, which is necessary for the production of Er Dong Tang [1] - The completion of the pre-processing workshop expansion requires the successful verification of three batches of products and passing a compliance inspection organized by the drug regulatory authority [1]

Group 1 - The company is currently advancing the pre-treatment workshop expansion work necessary for the production of Er Dong Tang [2] - The completion of the pre-treatment workshop expansion requires the successful verification of three batches of products and passing the compliance inspection organized by the drug regulatory authority [2]

Market Overview - The Chinese medicine sector experienced a decline of 0.98% on February 2, with Jilin Aodong leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Weikang Pharmaceutical (300878) with a closing price of 27.93, up 6.68% [1] - Foci Pharmaceutical (002644) with a closing price of 9.21, up 4.66% [1] - Significant decliners included: - Jilin Aodong (000623) with a closing price of 18.88, down 7.63% [2] - Datang Pharmaceutical (920433) with a closing price of 5.86, down 3.46% [2] Trading Volume and Capital Flow - The Chinese medicine sector saw a net outflow of 235 million yuan from institutional investors, while retail investors contributed a net inflow of approximately 51.97 million yuan [2] - The trading volume for Jilin Aodong reached 504,800 shares, with a transaction value of 977 million yuan [2] Individual Stock Capital Flow - Key capital flows for selected stocks included: - Dong'e Ejiao (000423) with a net inflow of 129 million yuan from institutional investors, but a net outflow of 18.04 million yuan from retail investors [3] - Foci Pharmaceutical (002644) had a net inflow of 43.42 million yuan from institutional investors, with a net outflow of 15.68 million yuan from retail investors [3]